COLORADO SPRINGS, Colo., Sept. 29, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, has entered into a laboratory services agreement with ImmunoClin Corporation (IMCL) through its wholly-owned UK subsidiary, ImmunoClin Ltd., a healthcare company with over thirteen years’ experience in providing premiere laboratory and related pre-clinical and clinical research services on a commercial scale.

“With ImmunoClin’s track record in assisting biotech, pharma and food companies as well as public institutions in pharmaceutical and nutraceutical development projects, we are excited to initiate this long-term relationship between ImmunoClin and CBIS in the cannabinoid research field. We further benefit from the fact that ImmunoClin’s founder, Dr. Dorothy Bray, is a clinical development expert and serves at present as the Director, President and CEO of both Companies, thereby assuring smooth and effective collaboration,” stated Mr. Mario S. Lap, Director and President of European Operations, Cannabis Science, Inc.

“With the contract in place, we intend to move quickly and efficiently to assist Cannabis Science in developing proprietary formulations to bring its cannabinoid based products to patients in need,” said Khadija Benlhassan, Ph.D., Director and Chief Scientific Officer, ImmunoClin Corporation.

Cannabis Science anticipates that ImmunoClin will commence cannabinoid-based drug formulation at its laboratories within the coming weeks, including advanced development of Cannabis Science’s proprietary neurological drug, tentatively designated as “CS-Neuro-1". This contract complements the Company’s agricultural and research programs in Spain, Italy and other European countries.

“Cannabis Science looks forward to working with ImmunoClin in the development of CS-Neuro-1, CS-TATI-1, CS-S/BCC-1, and other products in the Cannabis Science pipeline that we strongly believe will improve the lives of people around the world,” concluded Mr. Lap.

About ImmunoClin Corporation

ImmunoClin Corporation is a United States healthcare company with principal office in Washington, DC, USA, European headquarters and laboratory facilities in London, United Kingdom and laboratories in central Paris, France. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer’s disease. In addition, ImmunoClin provides select third-party companies with specialized laboratory and research services.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658

Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824

Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788

SOURCE Cannabis Science, Inc.